Blood As a Substitute for Tumor Tissue in Detecting EGFR Mutations for Guiding EGFR TKIs Treatment of Nonsmall Cell Lung Cancer: A Systematic Review and Meta-Analysis

Overview

Journal Medicine (Baltimore)

Specialty General Medicine

Date 2015 May 29

PMID 26020382

Citations 35

Authors

Chen Mao

Jin-Qiu Yuan

Zu-Yao Yang

Xiao-Hong Fu

Xin-Yin Wu

Jin-Ling Tang

Affiliations

Soon will be listed here.

Abstract

Tumor tissues are often absent or insufficient for testing epidermal growth factor receptor (EGFR) mutations to guide EGFR tyrosine kinase inhibitors (TKIs) treatment of patients with nonsmall cell lung cancer (NSCLC). We conducted this systematic review and meta-analysis to assess whether blood can be used as a substitute for tumor tissue in detecting EGFR mutations. MEDLINE, EMBASE, and the Cochrane Library were searched for studies that provided data to estimate the accuracy of blood testing against tissue testing in NSCLC patients and/or those directly compared the efficacy of EGFR TKIs in EGFR mutant and wild-type patients according to sources of specimens. Sensitivity, specificity, and concordance rate were used as measures of the accuracy. Risk ratio (RR) for objective response and hazard ratio (HR) for progression-free survival (PFS) and overall survival (OS) were used as measures for treatment efficacy. We combined the effects by using the fixed-effects model unless there was evidence of heterogeneity, in which case a random-effects mode was used. This systematic review included 25 studies with 2605 patients. The pooled overall sensitivity, specificity, and concordance rate were 0.61, 0.90, and 0.79, respectively. Serum showed lower sensitivity (0.56 vs 0.65) but higher specificity (0.95 vs 0.85) and higher concordance (0.86 vs 0.74) than plasma. EGFR mutations (exon 19 or 21) in blood were significantly associated with objective response (RR: 4.08; 95% confidence interval [CI] 2.48-6.70), PFS (HR: 0.72; 95% CI 0.64-0.80), and OS (HR: 0.71; 95% CI 0.50-0.99). Importantly, the association of the mutations with the 3 clinical outcomes for serum was similar to that for tumor tissue and higher than that for plasma. Blood, in particular serum, is a good substitute when tumor tissue is absent or insufficient for testing EGFR mutations to guide EGFR TKIs treatment in patients with NSCLC. EGFR mutation positivity in blood could be used to recommend EGFR TKIs treatment, but the absence of blood positivity should not necessarily be construed with confirmed negativity.

Citing Articles

The Role of ctDNA in the Management of Non-Small-Cell Lung Cancer in the AI and NGS Era.

Costa J, Membrino A, Zanchetta C, Rizzato S, Cortiula F, Rossetto C Int J Mol Sci. 2025; 25(24.

PMID: 39769431 PMC: 11727717. DOI: 10.3390/ijms252413669.

Clinical Utility and Application of Liquid Biopsy Genotyping in Lung Cancer: A Comprehensive Review.

Nigro M, Marchese P, Deiana C, Casadio C, Galvani L, Di Federico A Lung Cancer (Auckl). 2023; 14:11-25.

PMID: 36762267 PMC: 9904307. DOI: 10.2147/LCTT.S388047.

Circulating Mutations in Patients with Lung Adenocarcinoma by Circulating Tumor Cell Isolation Systems: A Concordance Study.

Li S, Wu M, Wang H, Hsu P, Fang Y, Wang C Int J Mol Sci. 2022; 23(18).

PMID: 36142574 PMC: 9505961. DOI: 10.3390/ijms231810661.

The Presence of EGFR T790M in TKI-Naïve Lung Cancer Samples of Patients Who Developed a T790M-Positive Relapse on First or Second Generation TKI Is Rare.

Li W, Kok K, Tan G, Meng P, Mastik M, Rifaela N Cancers (Basel). 2022; 14(14).

PMID: 35884570 PMC: 9320221. DOI: 10.3390/cancers14143511.

Using All Our Genomes: Blood-based Liquid Biopsies for the Early Detection of Cancer.

Adams E, Sepich-Poore G, Miller-Montgomery S, Knight R View (Beijing). 2022; 3(1).

PMID: 35872970 PMC: 9307139. DOI: 10.1002/VIW.20200118.

References

Sequist L, Heist R, Shaw A, Fidias P, Rosovsky R, Temel J . Implementing multiplexed genotyping of non-small-cell lung cancers into routine clinical practice. Ann Oncol. 2011; 22(12):2616-2624. PMC: 3493130. DOI: 10.1093/annonc/mdr489. View

Huang Z, Wang Z, Bai H, Wu M, An T, Zhao J . The detection of EGFR mutation status in plasma is reproducible and can dynamically predict the efficacy of EGFR-TKI. Thorac Cancer. 2017; 3(4):334-340. DOI: 10.1111/j.1759-7714.2012.00133.x. View

He C, Liu M, Zhou C, Zhang J, Ouyang M, Zhong N . Detection of epidermal growth factor receptor mutations in plasma by mutant-enriched PCR assay for prediction of the response to gefitinib in patients with non-small-cell lung cancer. Int J Cancer. 2009; 125(10):2393-9. DOI: 10.1002/ijc.24653. View

Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun M . Cancer statistics, 2009. CA Cancer J Clin. 2009; 59(4):225-49. DOI: 10.3322/caac.20006. View

Sriram K, Tan M, Savarimuthu S, Wright C, Relan V, Stockwell R . Screening for activating EGFR mutations in surgically resected nonsmall cell lung cancer. Eur Respir J. 2011; 38(4):903-10. DOI: 10.1183/09031936.00190110. View

Sozzi G, Conte D, Leon M, Ciricione R, Roz L, Ratcliffe C . Quantification of free circulating DNA as a diagnostic marker in lung cancer. J Clin Oncol. 2003; 21(21):3902-8. DOI: 10.1200/JCO.2003.02.006. View

Brevet M, Johnson M, Azzoli C, Ladanyi M . Detection of EGFR mutations in plasma DNA from lung cancer patients by mass spectrometry genotyping is predictive of tumor EGFR status and response to EGFR inhibitors. Lung Cancer. 2010; 73(1):96-102. PMC: 3282180. DOI: 10.1016/j.lungcan.2010.10.014. View

Chen Y, Fan W, Tseng P, Tsai C, Chou T, Wu C . Plasma epidermal growth factor receptor mutation analysis and possible clinical applications in pulmonary adenocarcinoma patients treated with erlotinib. Oncol Lett. 2012; 3(3):713-717. PMC: 3362392. DOI: 10.3892/ol.2011.534. View

Akca H, Demiray A, Yaren A, Bir F, Koseler A, Iwakawa R . Utility of serum DNA and pyrosequencing for the detection of EGFR mutations in non-small cell lung cancer. Cancer Genet. 2013; 206(3):73-80. DOI: 10.1016/j.cancergen.2013.01.005. View

10.

Shih J, Gow C, Yu C, Yang C, Chang Y, Tsai M . Epidermal growth factor receptor mutations in needle biopsy/aspiration samples predict response to gefitinib therapy and survival of patients with advanced nonsmall cell lung cancer. Int J Cancer. 2005; 118(4):963-9. DOI: 10.1002/ijc.21458. View

11.

Maheswaran S, Sequist L, Nagrath S, Ulkus L, Brannigan B, Collura C . Detection of mutations in EGFR in circulating lung-cancer cells. N Engl J Med. 2008; 359(4):366-77. PMC: 3551471. DOI: 10.1056/NEJMoa0800668. View

12.

Kuang Y, Rogers A, Yeap B, Wang L, Makrigiorgos M, Vetrand K . Noninvasive detection of EGFR T790M in gefitinib or erlotinib resistant non-small cell lung cancer. Clin Cancer Res. 2009; 15(8):2630-6. PMC: 2727796. DOI: 10.1158/1078-0432.CCR-08-2592. View

13.

Mantel N, Haenszel W . Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst. 1959; 22(4):719-48. View

14.

DerSimonian R, Laird N . Meta-analysis in clinical trials. Control Clin Trials. 1986; 7(3):177-88. DOI: 10.1016/0197-2456(86)90046-2. View

15.

Shepherd F, Pereira J, Ciuleanu T, Tan E, Hirsh V, Thongprasert S . Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med. 2005; 353(2):123-32. DOI: 10.1056/NEJMoa050753. View

16.

Mack P, Holland W, Burich R, Sangha R, Solis L, Li Y . EGFR mutations detected in plasma are associated with patient outcomes in erlotinib plus docetaxel-treated non-small cell lung cancer. J Thorac Oncol. 2009; 4(12):1466-72. DOI: 10.1097/JTO.0b013e3181bbf239. View

17.

Soeken K, Sripusanapan A . Assessing publication bias in meta-analysis. Nurs Res. 2003; 52(1):57-60. DOI: 10.1097/00006199-200301000-00009. View

18.

Kris M, Natale R, Herbst R, Lynch Jr T, Prager D, Belani C . Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA. 2003; 290(16):2149-58. DOI: 10.1001/jama.290.16.2149. View

19.

Punnoose E, Atwal S, Liu W, Raja R, Fine B, Hughes B . Evaluation of circulating tumor cells and circulating tumor DNA in non-small cell lung cancer: association with clinical endpoints in a phase II clinical trial of pertuzumab and erlotinib. Clin Cancer Res. 2012; 18(8):2391-401. DOI: 10.1158/1078-0432.CCR-11-3148. View

20.

Bai H, Mao L, Wang H, Zhao J, Yang L, An T . Epidermal growth factor receptor mutations in plasma DNA samples predict tumor response in Chinese patients with stages IIIB to IV non-small-cell lung cancer. J Clin Oncol. 2009; 27(16):2653-9. DOI: 10.1200/JCO.2008.17.3930. View